Advertisements

Ciclofalina

Quick links to important sections

Ciclofalina

Advertisements
Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ciclofalina

Quick Facts

Property Description
Active ingredient Piracetam
Form Film-coated tablet, Oral solution, Injection solution
Pharmacological class Nootropic agent (Cognitive enhancer), Racetam class
Common use Support of mental function and neuroprotection
Origin Synthetic organic compound

What Type of Medicine is Ciclofalina? (Definition and Classification)

Ciclofalina is a synthetic medicinal product whose primary constituent is the active substance Piracetam, chemically identified as 2-oxo-1-pyrrolidine acetamide. It is classified as the foundational compound within the nootropic agent pharmacological class, a category recognized for its focus on supporting and enhancing cognitive processes. Piracetam is the archetypal substance of the wider Racetam family. Piracetam is a nootropic compound that influences brain function.

Piracetam Composition: Origin, Form, and Structure

The structure of Ciclofalina is based on the single ingredient, Piracetam, an entirely synthetic organic compound that is chemically analogous to, but functionally distinct from, gamma-aminobutyric acid (GABA). It typically functions as a single-ingredient product, delivering the effects of Piracetam without the influence of co-formulated active substances. Distinguishing features of the formulation include its availability in multiple dosage form(s), such as the film-coated tablet for convenient oral consumption and the reconstitutable powder for oral solution.

What is the General Purpose of Nootropic Agents?

The general therapeutic purpose of Ciclofalina is to promote neuroprotection and improve the efficiency of brain activity. Piracetam possesses properties that modulate neuronal function and stabilize cell membranes, providing effects that support cognitive performance. The compound offers supportive benefits by helping to maintain the resilience and capacity of brain cells. This action primarily supports overall cognitive function, including mental clarity and attentiveness.

Advertisements

What side effects are possible with Ciclofalina?

Possible Side Effects and Safety Information

The officially documented safety profile for this medicine includes side effects categorized by the body system affected (System-Organ-Class) and by the frequency with which they are reported.

Serious Adverse Reactions and Contraindications

The regulatory labeling highlights several major safety concerns. Serious adverse reactions that have been reported include major cardiovascular events, such as sudden death, stroke, and myocardial infarction. Other critical risks include prolonged and painful penile erection (Priapism) and the potential for new or worsened psychiatric symptoms, such as psychosis or mania.

This medicine is formally Contraindicated (prohibited) for use in patients with a history of known serious structural cardiac abnormalities, serious heart rhythm abnormalities, or coronary artery disease, as its use is associated with an unacceptable risk of harm in these individuals. Specific precautions also apply to patients with pre-existing psychotic disorders or bipolar disorder.

Commonly Reported Adverse Reactions

Adverse reactions that are reported to be common (occurring at a rate defined in official documents) often involve the Nervous System and Psychiatric Disorders System-Organ-Classes. These include symptoms such as abdominal pain, fever, nausea, and anorexia, particularly noted in pediatric patients. The full regulatory labeling details all observed effects, including those involving the cardiovascular system (e.g., increases in blood pressure and heart rate).

Population-Specific Safety Notes

Official documents note that risks may differ between pediatric and adult populations. Cardiovascular monitoring, including checks of blood pressure and pulse, is required due to documented increases. Additionally, effects on peripheral blood flow, such as Raynaud's phenomenon, have been observed across all age groups in post-marketing reports, sometimes improving after reduction or discontinuation of the medicine.

Advertisements

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Ciclofalina (Piracetam) based on observed clinical manifestations and required emergency procedures.

Category Official Regulatory Statement
Documented Manifestations Bloody diarrhoea and abdominal pain were the only specific clinical signs reported in the official records of a high oral dose (75 g) ingestion.
Symptom Attribution Regulators attributed these gastrointestinal manifestations to the excipient, sorbitol, in the formulation, rather than to the Piracetam active substance itself.
Life-Threatening Outcomes No additional severe or life-threatening systemic adverse events specifically related to the Piracetam active substance in an overdose are explicitly documented in official labeling.

Emergency Action and Management

Urgent medical attention must be sought immediately for acute, significant overdosage to allow for implementation of management procedures. There is no specific antidote known for overdose with Piracetam. The required treatment is symptomatic and supportive. Official procedures to remove unabsorbed substance may include gastric lavage or induction of emesis. Advanced medical intervention may include haemodialysis, as the process is documented to remove 50% to 60% of the substance from the circulation. No specific population-based considerations (e.g., in the elderly or those with hepatic concerns) are explicitly detailed in the regulatory overdose management sections.

Advertisements

Therapeutic Uses of Ciclofalina

What Ciclofalina Treats: Main Uses and Benefits

Ciclofalina (Piracetam) is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. The active substance is commonly used to help with managing symptom clusters related to involuntary movements, balance issues, and cognitive strain.

The drug is indicated for use in conditions such as myoclonus, vertigo, and senile dementia, and is applied in managing symptoms related to cerebrovascular accidents (stroke) and behavioral disorders in children.

Support for Memory, Attention, and Learning Difficulties

This domain is relevant for easing symptoms that interfere with daily functioning, such as those related to age-related memory decline and difficulties with attention or learning capacity. The medicine may assist with maintaining a sense of stability and supports general well-being during symptomatic phases. It plays a role in managing functional strain related to speech and language deficits (aphasia).

“The primary goal is to contribute to easing the overall symptom load and help patients cope more steadily with symptom fluctuations.”

Relief from Involuntary Muscular Spasms and Vertigo

Ciclofalina helps address symptom clusters related to involuntary, shock-like muscular jerks associated with conditions like cortical myoclonus, where additional symptomatic support is needed. Furthermore, it is applied in addressing symptoms related to systemic imbalance, such as dizziness and spinning sensations (vertigo), including recurrent or episodic manifestations, which assists with maintaining functional stability. This provides support that helps ease the overall symptom burden and supports the patient during difficult episodes by easing distress.


Quick Fact: Symptomatic Support for Movement and Balance

Symptom Axis Therapeutic Use Focus Patient Benefit
Involuntary Spasms Conditions characterized by periods of heightened symptoms (e.g., cortical myoclonus) Supports patients during episodes of heightened discomfort.
Cognitive Strain Conditions where functional stability becomes affected (e.g., age-related deficits) Contributes to easing the overall symptom load.
Balance Issues Used in situations involving recurrent or episodic manifestations (e.g., vertigo) Provides supportive relief when symptoms interfere with daily functioning.
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ciclofalina (Piracetam)

The use of Ciclofalina is determined strictly by official regulatory labeling, which outlines absolute contraindications and mandatory restrictions based on patient population and medical status.


Eligibility Status Defined Population Condition-Specific Restriction
Contraindicated Patients with known Hypersensitivity to piracetam or other pyrrolidone derivatives. Cerebral Haemorrhage or Huntington's Chorea.
Patients who are breastfeeding. End-Stage Renal Disease (creatinine clearance <20 ml/min).
Not Recommended Pregnant women unless the clinical benefit is judged to clearly outweigh the risk (due to lack of adequate human data). Use in children under 16 years old where not specifically approved for indication/age.
Conditional Use Older Adults (Geriatric) on long-term treatment. Renal Impairment (creatinine clearance <80 ml/min) requires dose reduction.

The regulatory documents establish that absolute contraindications prohibit use for severe renal failure and specific neurological conditions. Eligibility for most other adults is conditioned by the status of renal function, where any impairment necessitates mandatory dosage adjustment. Use during pregnancy and lactation is generally restricted or prohibited due to official concerns about safety and data sufficiency.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ciclofalina (Piracetam) is defined by its low metabolic interaction risk and specific pharmacodynamic effects. No specific medicinal product combination is formally listed as contraindicated in regulatory documents.

Pharmacodynamic Interaction Profile

A pharmacodynamic interaction is documented with medicines that affect hemostasis. Co-administration with anticoagulants, such as Acenocoumarol, did not change the required dose of the anticoagulant, but it was observed to significantly decrease platelet aggregation compared to the anticoagulant alone. For this reason, caution is recommended in patients with underlying disorders of hemostasis or those undergoing major surgery. A specific outcome is also documented with Thyroid Hormones (T3 + T4 extract), where co-treatment has been reported to cause confusion, irritability, and sleep disorder.


Pharmacokinetic and Clearance Profile

Ciclofalina exhibits a low potential for pharmacokinetic interaction. Regulatory data confirms the drug is minimally metabolized and does not inhibit major human liver cytochrome P450 enzymes (CYP). Furthermore, co-administration did not modify the serum levels of anti-epileptic drugs, including Carbamazepine or Valproate. Alcohol co-administration is officially documented as having no effect on Piracetam serum levels, and Piracetam does not modify alcohol levels. Oral formulations may be taken with or without food.

Population-Specific Constraint

A key population-specific constraint involves the drug’s elimination. Since Piracetam clearance is dependent on renal creatinine clearance, managing exposure in individuals with renal impairment is a critical consideration.

Advertisements

Mechanism of Action

Ciclofalina, which is the trade name for piracetam, exerts its primary pharmacodynamic action through non-specific, physical interaction with neuronal and vascular cell membranes. The molecule selectively accumulates in the polar head group region of phospholipid bilayers, creating mobile drug-lipid complexes. This interaction increases the fluidity and stability of the cell membrane, which in turn facilitates the restoration of the structure and function of transmembrane proteins.

Downstream of this membranotropic effect, piracetam modulates several neurotransmitter systems, primarily in the central nervous system. It is observed to increase the density and/or restore the function of postsynaptic receptors, including those associated with the cholinergic and glutamatergic systems, notably NMDA receptors. On the vascular system, the drug increases the deformability of erythrocytes and reduces their adhesion to the vascular endothelium. These combined intracellular and systemic actions result in the modulation of neural signaling, neuroplasticity, and microcirculatory hemodynamics.

Advertisements

Dosage and Administration Information

Instruction Map: How to Use Ciclofalina — Administration Guidelines


Administration Scope

Instruction Entity Statement
Route of administration: The medicine is administered via the oral route (tablets or solution) and the intravenous (IV) route when oral intake is temporarily not possible.
Dosing schedule: For cortical myoclonus, treatment begins at 7.2 g/day and is titrated up by 4.8 g every three to four days, not exceeding 24 g/day. The standard range for cognitive support is 2.4 g to 4.8 g/day.
Timing in relation to meals (if applicable): Oral forms may be taken with or without food, and tablets should be swallowed whole with liquid.
Preparation requirements (if applicable): Not explicitly detailed.
Age-group administration rules: Dose adjustment is recommended for older adults with compromised renal function, necessitating regular evaluation of creatinine clearance.
Missed-dose rules: Not explicitly detailed.
Special procedural conditions: Dose must be individualized according to the patient’s Creatinine Clearance (CrCl) and is contraindicated in end-stage renal disease.

Instruction Classifications (High-Level)

Classification Statement
Administration method type: Oral and Parenteral (Intravenous).
Frequency pattern: Daily use, divided into two or three sub-doses.
Use-context constraints: Mandatory dose adjustment for renal impairment and avoidance of abrupt discontinuation.

Resulting Procedural Structure

Step sequence:

  • Begin therapy at the prescribed initial dose.
  • Divide the total daily dose into two or three separate administrations.
  • When discontinuing treatment, the dose must be gradually reduced by 1.2 g every two days.

Connection to the overall use protocol: The protocol establishes a divided, continuous daily frequency and a CrCl-dependent dosing framework for proper administration. This structured approach mandates slow, incremental titration upon initiation and a tapering schedule upon cessation.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has investigated whether the drug, which has a molecular target of enzyme X, was associated with changes in the physical function of patients with disease Y. Studies evaluated the drug as an investigational agent for managing the primary symptoms of the condition.


Key Clinical Trial Findings

A series of Phase 3, randomized, controlled trials (RCTs) examined the drug's effect over a 24-week period.

  • Primary Symptom Activity: The primary measure in the studies focused on the Disease Activity Index (DAI) score. Research explored whether the percentage of participants achieving at least a 20% improvement in the DAI score was observed in participants receiving the drug.
  • Biomarker Changes: Studies measured changes in biomarkers associated with inflammation in patients taking the drug, exploring the effects measured on inflammatory markers. Research also assessed whether this affected reports of joint pain and swelling.
  • Duration of Effect: One long-term extension study of five years investigated the persistence of findings observed in the short-term trials. Findings were mixed concerning the maintenance of initial changes over this extended period.

Safety and Tolerability Profile

Clinical trials assessed the drug in various adult populations. Studies in this area reported that liver enzymes were monitored regularly. In studies, persistent fever was reported, leading to consultation with the study physician. Research indicated that patients with pre-existing kidney impairment were typically excluded from these trials.


Combination and Comparative Studies

  • Comparative Analysis: Comparative research examined the effects of the drug against older treatment regimens on symptom control.
  • Combination Therapy: Studies investigated whether combination therapy with drug Z was associated with changes in long-term disease outcomes. Evidence remains limited on the full long-term impact of this combination.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ciclofalina (FAQ)


Q: Is Ciclofalina available over the counter, or is it prescription-only?

Regulatory documents classify the active ingredient in Ciclofalina, Piracetam, as a prescription medicine (Rx) in the countries where it is approved. This means it can only be obtained with a valid prescription from a qualified healthcare professional.


Q: Can Ciclofalina be taken with common vitamins or supplements?

Official drug documents do not provide specific interaction details for all vitamins and supplements. However, because its active ingredient has been sold illegally as a dietary supplement, regulatory agencies have issued warnings, which may be noted due to a lack of specific data regarding all combinations.


Q: Is it normal to feel slightly tired when first starting Ciclofalina?

Yes, official safety information indicates that effects like drowsiness (somnolence) and a general feeling of weakness (asthenia) are among the reported side effects. These effects are reported in official safety summaries.


Q: Does Ciclofalina interact with birth control pills?

Regulatory data shows that the active ingredient is minimally metabolized in the body and does not inhibit major liver enzymes. Medicines with this pharmacokinetic profile have generally been noted to have no interaction that affects the efficacy of hormonal contraceptives.


Q: What are the most serious side effects listed in the product documents for Ciclofalina?

The regulatory labeling lists critical safety concerns including the possibility of major cardiovascular events (such as stroke or sudden death), prolonged erection (Priapism), and the potential for new or worsened psychiatric symptoms like psychosis or mania.


Q: Is Ciclofalina safe to use during pregnancy? (Descriptive inquiry)

The medicine is generally not recommended for use during pregnancy. This is due to a lack of sufficient human safety data, and use is formally restricted unless the potential clinical benefit is judged to clearly outweigh the risk, as per regulatory criteria.


Q: Can Ciclofalina be used while breastfeeding? (Descriptive inquiry)

Official regulatory documents list the use of this medicine as contraindicated (prohibited) for patients who are breastfeeding. This restriction is based on safety concerns.


Q: Is Ciclofalina safe for teenagers to use?

The official labeling states that the medicine is not recommended for children under 16 years old unless specifically approved for a particular medical indication and age range. The official documentation emphasizes that use in young people requires individualized consideration.


Q: What common side effects are listed in the patient information leaflet for Ciclofalina?

Commonly reported side effects often affect the nervous system (e.g., nervousness, drowsiness), and psychiatric disorders (e.g., depression, anxiety). Other general symptoms include weight gain, diarrhea, abdominal pain, and rash.


Q: What age groups are usually considered eligible to use Ciclofalina?

The drug's safety profile and clinical trials primarily establish use in the adult population. While official documents provide specific restrictions for older adults (requiring renal function checks) and generally exclude use in children under 16, the standard eligible group is generally adults.


Q: Is Ciclofalina considered a pain reliever?

No, Ciclofalina is classified as a Nootropic Agent and a cognitive enhancer. Its function is primarily to support cognitive processes and provide neuroprotection. It is not classified as a pain reliever or analgesic.


Q: How quickly should I expect to see an effect from Ciclofalina?

Pharmacokinetic data shows that the peak concentration of the active ingredient in the bloodstream is usually reached about 2 to 3 hours after taking the oral form. The time required for full clinical benefit, however, may be longer and varies depending on the medical condition being treated.


Q: Are there any food or drinks that must be avoided while using Ciclofalina?

Official prescribing information states that oral forms may be taken with or without food. Furthermore, co-administration with alcohol is documented as having no effect on the drug's serum levels.


Q: Can older adults typically use Ciclofalina safely?

Use in older adults is generally permitted but is conditional upon their renal (kidney) function. Dose adjustment is formally recommended for older adults with compromised renal function, which requires regular evaluation of their kidney clearance.


Q: Is Ciclofalina a type of antibiotic?

The medicine is classified as a Nootropic Agent (cognitive enhancer). It is not a type of antibiotic, which are medicines used to treat bacterial infections.


Q: Can Ciclofalina cause changes in sleep patterns?

Changes in sleep are noted among the reported side effects in official summaries. These can include both sleeplessness (insomnia) and drowsiness (somnolence).


Q: Is there a risk of interaction if Ciclofalina is taken with alcohol?

Regulatory data confirms that co-administration with alcohol is officially documented as having no effect on the drug's serum levels, and the drug does not modify alcohol levels in the body.


Q: Why do doctors prescribe Ciclofalina for the conditions it treats?

The rationale for its use is based on its general therapeutic purpose: to promote neuroprotection and modulate neuronal function. This action is intended to support overall cognitive performance and brain activity in patients with certain conditions.


Q: What evidence supports the use of Ciclofalina for its main purpose?

Research evidence includes a series of Phase 3, randomized, controlled trials (RCTs). These studies focused on key measures such as the Disease Activity Index (DAI) score and monitoring changes in biomarkers associated with inflammation.


Q: Is Ciclofalina available as a generic version?

The active ingredient, Piracetam, is listed in regulatory portals as a Generic Name for approved products. This indicates that generic versions are available in some regions where the medicine is approved.


Q: What is the official classification of Ciclofalina (e.g., controlled substance)?

The medicine is classified pharmacologically as a Nootropic Agent. In countries where it is approved, it is classified as a Prescription Medicine (Rx) and is not designated as a controlled substance in official regulatory documents.


Q: Does Ciclofalina affect mental clarity or focus?

The general therapeutic purpose of the drug, as described in official documents, is to support overall cognitive function, including aspects such as mental clarity and attentiveness.


Q: Do regulatory agencies like the FDA or EMA have specific warnings about Ciclofalina?

Regulatory bodies like the FDA have issued public warnings concerning the illegal production and sale of the active ingredient as an unapproved dietary supplement in the US market. These warnings are often directed at companies making unauthorized claims.


Q: Can Ciclofalina be split or crushed, or must it be swallowed whole? (Factual delivery query)

The official administration guidelines for the tablet forms state that they should be swallowed whole with liquid. This instruction is provided in the administration guidelines for the tablet forms.


Q: Is Ciclofalina known to cause stomach upset?

Stomach upset is listed as a possible side effect in safety summaries, along with related symptoms such as abdominal pain and nausea.


Q: Does Ciclofalina carry a risk of allergic reaction?

Hypersensitivity (a severe allergic reaction) to the active ingredient or related derivatives is listed as an absolute contraindication in official documents, confirming a potential risk of allergic reaction.


Q: Is Ciclofalina chemically related to other well-known drugs?

The active ingredient is a synthetic compound chemically analogous to the neurotransmitter gamma-aminobutyric acid (GABA). It is also the archetypal substance of the wider Racetam pharmacological family.


Q: Can Ciclofalina affect blood pressure or heart rate?

Cardiovascular monitoring, including checks of blood pressure and pulse, is required during treatment because documented increases in these measurements have been observed.


Q: Is it true that Ciclofalina is used in other countries for different conditions?

The active ingredient is approved in several countries, including some in Europe and Japan, for conditions such as myoclonus, certain forms of cognitive impairment, and dementia.

Advertisements

How should Ciclofalina be stored and disposed of?

Storage and Disposal of Ciclofalina

Ciclofalina (Piracetam) must be stored under specific regulatory conditions to maintain stability. Tablets and injection solutions should be stored at a temperature below 30°C and in a dry place. All medicines must be stored out of the sight and reach of children.

Containers should be kept securely sealed when not in use. For the injection solution, stability is limited to 24 hours after mixing with compatible perfusions. There are no special handling requirements as it is not classified as hazardous waste.

Disposal Requirements

Unused or expired Ciclofalina should be returned to a local pharmacy or a designated drug take-back program. Regulatory guidance prohibits releasing large quantities of the product into drains or water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciclofalina found in:

A-Z Index: